Eczema severity as measured by EASI

EASI improvement shown with DUPIXENT® from baseline to week 161

Proportion of patients who achieved EASI-75 at week 16 vs. placebo (secondary endpoint)1†

Bar chart showing the percentage of patients in the SOLO 1, SOLO 2 and CHRONOS trials who achieved and EASI-75 response at Week 16. In the SOLO 1 trial, 51.3% DUPIXENT®-treated patients (n=224) versus 14.7% of placebo-treated patients (n=224) achieved an EASI-75 response. The p for this comparison is less than 0.0001. In the SOLO 2 trial, 44.2% DUPIXENT®-treated patients (n=233) versus 11.9% of placebo-treated patients (n=236) achieved an EASI-75 response. The p for this comparison is less than 0.0001. In the CHRONOS trial, 68.9% of patients treated with DUPIXENT plus topical corticosteroids (n=106) and 23.2% of patients treated with placebo plus topical corticosteroids (n=315) achieved an EASI-75 response. The p value for this comparison is less than 0.0001.

Eczema Area and Severity Index (EASI)

The EASI questionnaire is a tool used to measure the extent (area) and severity of AD. The score ranges from 0-72, with higher scores indicating more severe AD.10

The severity of AD lesions is assessed on four parameters10

Photographs showing how the four parameters of the EASI score are assessed. Patients can receive a score of 0 to 3 in each of four parameters: erythema, edema/papulation, excoriation, and lichenification, a score of 0 indicating that the parameter is not present, 1 indicating that the parameter is mild, 2 indicating that the parameter is moderate, and 3 indicating that the parameter is severe. Patients receive a score of 1 for erythema that’s faintly detectable and pink, edema and papulation with barely perceptible elevation, scant and superficial excoriation, and lichenification with slight, thin thickening and markings that are minimally exaggerated. Patients receive a score of 2 for erythema that’s a clearly distinguishable dull red, edema or papulation with clearly perceptible elevation but not prominent, many superficial and/or some deep excoriations, and for lichenification, if they have thickened skin with exaggerated markings and/or some prurigo nodules. Patients receive a score of 3 for  erythema that’s deep dark or fiery bright red, edema or papulation that’s prominently elevated, extensive superficial and/or deep excoriations, and for lichenification, if they have exaggerated markings creating deep furrows and/or many prurigo nodules.

Find out how to calculate your patient’s EASI


Dosing and Administration

Thinking about prescribing DUPIXENT®? Find helpful information to get started.
 

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.
 



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300298
Last updated: 06/2023

paab logo